1 MEDICATIONS USED IN SUBSTANCE USE TREATMENT AND RECOVERY Carl M. Dawson, M.S., MAC, LPC - National Drug Court Institute ( NDCI ) Washington, D. C. - The School of Professional Psychology at Forest Institute Springfield, Missouri ( )
2 OUTLINE THE USE OF MEDICATIONS IN TREATMENT KEEPING OUR PERSPECTIVE MEDICATIONS OF REFERENCE. SEVEN ( 7 ) NEUROTRANSMITTERS OF IMPORTANCE. THE USE OF ANTI DEPRESSANTS. ANTI ALCOHOL MEDICATIONS ANTI COCAINE MEDICATIONS. AN INTRODUCTION TO OPIOIDS ANTI OPIOID MEDICATIONS.
3 KEEPING OUR PERSPECTIVE IN TREATMENT EVERY INDIVIDUAL THAT ENTERS INTO THE PROCESS OF RECOVERY IS CURSED WITH KNOWING THAT THEY POSSESS ONE MORE RELAPSE... WHAT THEY DON T KNOW... IS HOW MANY MORE OPPORTUNITES, IF EVER, THEY WILL HAVE TO RECOVER! REMEMBER...
4 ... our primary goal during the early months of recovery is not to focus on the idea of long term sobriety, but to keep the person from relapsing. Relapse is and will always be our enemy. During early recovery, focus on teaching the individual(s) how not to relapse and what it will take for them to stay drug free long enough until they feel confident about not using, and experienced enough time to reestablish a new life without the use mood altering substances. THEREFORE...
5 ...THE COMPLETE ABSTANCE FROM THE USE OF ALL MOOD ALTERING SUBSTANCES, INCLUDING THE INDIVIDUALS LEAST DRUG OF CHOICE, SHOULD BE THE FUNDAMENTAL PHILOSOPHY OF EVERY EFFECTIVE RECOVERY AND RELAPSE PREVENTION PROGRAM. HOWEVER...
6 ... WE MUST KEEP IN MIND THAT CURRENTLY THERE ARE EFFECTIVE MEDICATIONS THAT ASSIST HEALTH CARE PROFESSIONALS IN TREATING PSYCHIATRIC DISORDERS, SLEEP DISORDERS, NEUROLOGICAL DISORDERS, AND PHYSICAL MEDICAL DISEASES. WE ARE IN PART AN CHEMICAL ORGANISM. FURTHERMORE...
7 ... WE CAN NOT IGNORE THAT SINCE 1966 SCIENTIFIC AND MEDICAL SOCIETIES HAS RESEARCHED SUBSTANCE USE AND HAS DETERMINED THAT CHEMICAL DEPENDENCY DISORDERS ARE A CONSEQUIENCE OF BIOLOGICAL, PSYCHOLOGICAL, PHYSICAL AND SOCIOLOGICAL FACTORS THUS, POSSESSING THAT SCIENTIFIC KNOWLEDGE AND CONVENTIONAL WISDOM... WE MUST ALL BE WILLING TO EMBRACE THE CURRENT UNDERSTANDING THAT WE ARE DEALING WITH A BIO CHEMICAL PSYCHOLOGICAL DISORDER... DEFINED BY A PROCESS... THAT BEGINS IN THE BRAIN. THEREFORE...
8 ... CONSIDER... THAT IN THE FUTURE, TREATMENT OF CHEMICAL DEPENDENCY DISORDERS WILL AND SHOULD INCLUDE THE PROPER BALANCE OF THERAPEUTIC INTERVENTIONS THAT INCLUDE, CONVENTIONAL COUNSELING TECHNIQUES, EDUCATION, PREVENTION, SELF HELP GROUPS, PSYCHOLOGY, MEDICINE, SPIRITUALITY AND CHEMISTRY.
9 THE COMMON NEURON
11 NEURONAL CHEMICAL COMMUNICATION
12 THE ACTIONS OF A COMMON NEURON
13 NEUROTRANSMITTERS INVOLVED IN CHEMICAL ABUSE AND DEPENDENCY
14 SEVEN ( 7 ) PRIMARY NEUROTRANSMITTERS INVOLVED IN SUBSTANCE ABUSE AND DEPENDENCY We are considered to possess Sixty ( 60 ) plus neurotransmitters / neuromodulators in the brain and nervous system. The Big Three ( 3 ) are the following : 1. Dopamine ( DA ) : Involved with pleasure, small and large motor movements and psychosis. 2. Serotonin ( 5ht ) : Involved with self - confidence, feelings of well - being and mood disorders. 3. Norepinephrine ( NE ) : Stimulates the brains fight or flight centers.
15 ANTI DEPESSANT MEDICATIONS AND THEIR USE IN SUBSTANCE USE DISORDERS
16 DESIGNER ANTI DEPRESSANT MEDICATIONS : THESE MEDICATIONS ARE SPECIFICALLY DESIGNED TO EFFECT EITHER SERIOTONIN ( 5HT ) OR NOREPINEPHRINE ( NE ) AND TO A LESSER EXTENT DOPAMINE ( DA ) NEUROTRANSMITTERS. THESE MEDICATIONS INCLUDE : 1. PROZAC ( 5HT ) 2. LEXAPRO ( 5HT ) 3. CELEXA ( 5HT ) 4. ZOLOFT ( 5HT ) 5. CYMBALTA ( 5HT & NE ) 6. WELLBUTRIN ( NE & DA ) THESE MEDICATIONS ARE EFFECTIVE FOR THE TREATMENT OF REACTIVE AND CLINICAL DEPRESSION. THESE MEDICATIONS HAVE BEEN FOUND TO BE EFFECTIVE IN TREATING SUBSTANCE ABUSE DISORDERS DUE TO THEIR INFLUENCE ON THE DOPAMINE ( DA ) SYSTEM.
17 NORMAL REUPTAKE OF DA, 5ht, NE
18 PSYCHIATRIC - ALCOHOL MOOD DISORDERS Higher than Normal Dopamine ( DA ) Normal Baseline Dopamine ( DA ) Below Normal Dopamine ( DA ) Depression Returns to Below Normal Dopamine ( DA ) Depression
19 ANTI ALCOHOL MEDICATIONS
20 THE ALCOHOL BREAKDOWN SEQUENCE ACETALALHIDE ADH IS VERY TOXIC TO THE BODY CO2 ALDH H2O ACETATE
21 ANTI ALCOHOL MEDICATIONS ANTABUSE : IS A MEDICINE DESIGNED TO STOP THE NORMAL BREAK DOWN OF ALCOHOL IN THE BODY. ANTABUSE : STOPS THE BREAKDOWN OF ALCOHOL AT THE ACETALDEHYDE STAGE. ACETALDEHYDE IS HIGHLY TOXIC TO THE BODY. DRINKING WHILE USING ANTABUSE WILL RESULT IN SIGNIFICANT PHYSICAL DISTRESS.
22 THE ALCOHOL BREAKDOWN SEQUENCE WITH ANTABUSE ADH ACETALALHIDE IS VERY TOXIC TO THE BODY AND WILL ACCUMULATE CAUSING A SEVERE TOXIC REACTIONS. CO2 H2O ACETATE ALDH
23 ANTI - ALCOHOL CRAVING MEDICATIONS
24 THREE ( 3 ) NEUROTRANSMITTERS INVOLVED IN ANTI ALCOHOL MEDICATIONS GABA : Sedates the over excited Brain, reduces anxiety, acts like a Sedative drug on the Brain. Glutamate : Activates the Under excited Brain, increases alertness, motivation to learn new information. Endorphins : Biological Pain Killers known as Opioids.
25 REGIONS IN THE BRAIN ASSOCIATED WITH CRAVINGS
26 ANTI ALCOHOL CONT. ACAMPROSATE ( CAMPRAL ) : IS DESIGNED TO QUICKLY RESTORE THE GLUTAMATE SYSTEM AFTER DRINKING. ALCOHOL WITHDRAWAL SYNDROME IS A HOMEOSTASIS FEED BACK RESPONSE INVOLVING AN EXCESSIVE RELEASE OF GLUTAMATE. ACAMPROSATE APPEARS TO DECREASE ALCOHOL CONSUMPTION, WHILE... NALTREXONE IS MORE EFFECTIVE IN MAINTAINING ABSTINENCE.
28 ANTI ALCOHOL CONT. NALTREXONE ( VIVITROL OR ReVia ) : A FULL OPIOID ANTAGONISTS ( BLOCKER ). NALTREXONE IS DESIGNED TO BLOCK THE RAPID RELEASE OF ENDORPHINS THAT SOME INDIVIDUALS REPORT EXPERIENCING WHEN CONSUMING A DRINK. BLOCKING THE ENDORPHINS RUSH REDUCES THE DESIRED EFFECTS OF ALCOHOL FOR APPROXIMATELY ( 30 ) DAYS.
30 ANTI COCAINE MEDICATIONS DEVELOPED BY DR. THOMAS KOSTEN BAYLOR MEDICAL SCHOOL, HOUSTON, TX.
31 REUPTAKE INHIBITION ( COCAINE )
32 COCAINE S MOLECULES ARE UNDECTABLE BY THE BODY S AUTOIMMUNE SYSTEM
33 DR. KOSNEN S CHEMICAL FINDS AND ATTACHES TO THE COCAINE MOLECULE ALLOWING THE AUTOIMMMUNE SYSTEM TO THEN IDENTIFY AND DISABLE THE MOLECULE
34 AN INTRODUCTION TO OPIOID SUBSTANCES
35 What is an Agonist and an Antagonistic substance. An introduction to Opioid substances and how they impact the nervous system. Three ( 3 ) Therapeutic Objectives when treating Opioid abuse and dependence. The Therapeutic Dilemma when treating Opioid abuse and dependence. The Use of Medications In the Treatment of Opioid abuse, dependency and recovery. Methadone. Buprenophrine ( Subutex ). Buprenophrine and Naloxone ( Suboxone ). REGIONS OF BRAIN
36 FULL AGONIST ACCEPTS ALL OPIOID NEUROTRANSMITTERS
37 FULL ANTAGONIST REJECTS ALL OPIOID NEUROTRANSMITTERS
38 PARTIAL AGONIST ACCEPTS SOME & ANTAGONIST REJECTS OTHERS
39 HYPOTHETICAL DOSE RESPONSE CURVE FOR A FULL and PARTICAL Mu OPIOID AGONISTS INCREASING OPIOID EFFECTS FULL OPIOID AGONIST ( METHADONE ) ( CELILING ) PARTICAL OPIOID AGONIST ANITGONIST ( BUPRENORPHINE ) INCREASING ACUTE OPIOID DOSE
40 OPIOID DRUGS ARE CONSIDERED LOOK ALIKE NEUROTRANSMITTERS THE HUMAN BODY PRODUCES IT S OWN NATURAL PAIN FIGHTING SUBSTANCES CALLED ENDOGENOUS ( CREATED FROM THE INSIDE ) OPIOIDS. SYNTHETHIC OPIOIDS ARE MANUFACTERED SUBSTANCES CREATED IN A LABORATORY AND TAILORED TO MIMIC THE BODY S OWN ENDOGENOUS OPIOIDS.
41 THE THREE ( 3 ) PRIMARY OPIOID RECEPTORS Mu RECEPTORS : THE PRIMARY OPIOID RECEPTORS THAT HAVE THE STRONGEST ATTRACTION TO OPIOID SUBSTANCES... AND TRIGGER THE RELEASE OF PAIN AND PLEASURE PRODUCING CHEMICALS IN THE BRAIN. DELTA AND KAPPA OPIOID RECEPTORS ARE LESS ATTRACTIONED TO OPIOID SUBSTANCES IN THE BRAIN.
42 THE CENTRAL NERVOUS SYSTEM ( CNS ) CONSISTS OF THE BRAIN AND THE SPINAL CORD. THE GREATEST AMOUNT OF THE BODY S OPIOID ( Mu ) RECEPTORS ARE LOCATED THROUGHOUT THE BRAIN... LESS IN THE SPINAL CORD. FULL AGONIST RECEPTORS
43 OUR NERVOUS SYSTEM ( N.S. ) HAS A DETERMINED NUMBER OF OPIOID RECEPTORS, DESIGNED TO PROTECT US FROM PAIN.
44 HOWEVER, WHEN THE N.S. RECEIVES A GREATER THAN NORMAL AMOUNT OF OPIOIDS, OVER A PROLONGED PERIOD OF TIME, THE N.S. WILL NATURALLY REDUCE THE NUMBER OF RECEPTORS AVAILABLE IN ORDER TO LIMIT THE AMOUNT OF PLEASURE RELEASING CHEMICALS BEING ABSORBED BY THE BODY AND BRAIN. DOWN REG
45 THIS IS REFERRED TO AS DOWN REGULATION
46 THE PROCESS OF THE BRAIN DOWN REGULATING IT S SELF MAY RESULT IN EITHER SHORT - TERM ( TEMPORARY ) ABUSE SYMPTOMS OR LONG -TERM ( CHRONIC ) DEPENDENCY NEURONAL CHANGES. BUPRENOPHINE
47 THREE ( 3 ) THERAPEUTIC OBJECTIVES TO REMEMBER WHEN TREATING THE OPIOID DEPENDENT INDIVIDUAL...
48 ( FIRST ( 1 ST ) OBJECTIVE ) STOP THE ILLICIT DRUG USE! ( SECOND ( 2 ND ) OBJECTIVE ) ABSTAIN FROM THE USE OF ALL DRUGS... INCLUDING ALCOHOL!
49 THIRD ( 3 RD ) OBJECTIVE TO ELIMINATE THE OBSTICALES THAT LEAD TO RELAPSE! THAT INCLUDES CHANGING PEOPLE, PLACES, THINGS AND LIMITING CRAVINGS.
50 THE THERAPEUTIC DILEMMA SINCE OPIOID DEPENDENCE IS A MEDICAL / PHYSICAL DISORDER IMPACTING THE BRAIN... YOUR THERAPEUTIC DILEMMA IS...
51 ... WILL THE INDIVIDUAL S N.S. REBOUND ONCE THE OPIOID DRUGS ARE DISCONTINUED... OR HAS THE LONG -TERM USE OF OPIOID DRUGS CREATED A PERMINATE ( CHRONIC ) CHANGE IN THE BRAIN, REQUIRING THE USE OF OPIOID REPLACEMENT MEDICATIONS IN ORDER TO BE ABLE TO FUNCTION WITHOUT PAIN OR PHYSICAL CRAVINGS? THE FOLLOWING IS WHAT YOU MUST CONSIDER...
52 ... ASSUMING THAT THE BODY WILL NATURALLY REBOUND AND RETURN TO NORMAL... THE USE OF OPIOID REPLACEMENT MEDICATIONS MAY BE COMPLETELY UNNECESSARY... HOWEVER, IN LIMITED CIRCUMSTANCES OPIOID REPLACEMENT MEDICATIONS MAYBE AN IMPORTANT SHORT - TERM THERAPERUTIC OPTION, IN CONJUNCTION WITH CONVENTIONAL TREATMENT. IN THIS EVENT, OUR THERAPEUTIC MOTIVE WILL BE TO EVENTUALLY TAPER - DOWN AND DISCONTINUE THE USE OF OPIOID REPLACEMENT MEDICATIONS SAFELY OVER TIME.
53 HOWEVER... IF AN INDIVIDUALS CONTINUED AND CHRONIC USE OF OPIOID SUBSTANCES HAS PRODUCED NEUROLOGICAL CHANGES THAT HAS RESULTED IN OPIOID RECEPTOR DOWN REGULATION, THAN THE USE OF OPIOID REPLACEMENT MAINTANENCE MEDICATIONS MAY NEEDED IN ORDER TO AVOID RELAPSE AND THE EVENTUAL RETURN TO ILLICIT DRUG USING BEHAVIORS. THE FOLLOWING MEDICATIONS ARE CURRENTLY BEING USED IN LONG TERM OPIOID DEPENDENCE TREATMENT : 1. METHADONE 2. SUBUTEX 3. SUBOXONE
55 METHADONE TREATMENT IS FREQUENTLY REFERRED TO AS MAINTENANCE OR HARM REDUCTION THERAPY. METHADONE IS A LESS POWERFUL OPIOID MEDICATION THAT IS USED IN PLACE OF A MORE POWERFUL OPIOID SUBSTANCE ( HEROIN ). METHADONE IS A LONG ACTING OPIOID SUBSTANCE. METHADONE USE WILL TYPICALLY BLOCK OPIOID WITHDRAWAL SYMPTOMS FOR TWENTY FOUR ( 24 ) TO SEVENTY TWO ( 72 ) HOURS. ALTHOUGH LESS POWERFUL THAN HEROIN... METHADONE DOES CREATE A PHYSICAL DEPENDENCY AND CAN BE ABUSED AND DIVERTED.
56 BUPRENOPHINE ANTI OPIOID, ANTI - CRAVING MEDICATIONS ( SUBUTEX vs. SUBOXONE )
57 WHEN USED CORRECTLY, SUBUTEX AND SUBOXONE EMPLOY BUPRENOPHINE A HIGHLY STUBBORN AND LESS PHYSICALLY DEPENDENT PRODUCING OPIOID. BUPRENOPHINE, IS DESIGNED TO REPLENISH THE BODY AND BRAIN WITH NECESSARY PAIN FIGHTING SUBSTANCES, LOST DUE TO CHRONIC NEURONAL CHANGES ( DOWN REGULATION OF THE Mu RECEPTORS ) AND REDUCING THE DRUG S CRAVING CYCLES.
58 SUBUTEX THE MEDICATION SUBUTEX IS STRAIGHT BUPRENOPHINE... AND CAN BE ABUSED BY SIMPLY TAKING MORE THAN RECOMMENDED OR... BY COMBINING SUBTEX WITH OTHER OPIOIDS OR CENTRALLY ACTIVATING DEPRESSING DRUGS.
59 SUBUTEX ( BUPRENOPHRINE ONLY ) SUBUTEX CAN BE PRESCRIBED IN 2 mg and 8 mg DOSES. INTRODUCED INTO THE BODY VIA SUBLINGUAL ADMINISTRATION ( Under the Tongue ).
60 SUBOXONE THE MEDICATION CALLED SUBOXONE COMBINES BUPRENORPHINE WITH NALOXONE. ADDING NALOXONE TO BUPRENORPHINE REDUCES THE ABUSE OF OTHER OPIOID DRUGS, BY BLOCKING THEIR CHEMICAL ADMISSION INTO THE KAPPA OPIOID RECEPTORS. COMBINING NALOXONE WITH BUPRENOPRPHINE PREVENTS INTENTIONAL ABUSE, 1. EITHER BY OVER USE, 2. DIVERSIONARY TACTICS OR THROUGH ( I.V. ) INJECTIONS.
61 SUBOXONE ( BUPRENORPHINE WITH NALOXONE ). SUBOXONE CAN BE PRESCRIBED IN TWO ( 2 ) DOSES : (1). 2 mg of buprenorphine and 0.5 mg of naloxone. (2). 8 mg of buprenorphine and 2 mg of naloxone. INTRODUCED INTO THE BODY VIA SUBLINGUAL ADMINISTRATION ( Under the Tongue ).
62 HOWEVER, WHEN SUBOXONE IS BEING ABUSED, DIVERTED, OR COMBINDED WITH OTHER OPIOID DRUGS... THE ANTAGNONIST BLOCKING AGENT NALOXONE BECOMES ACTIVATED, REPLACING BUPRENOPHINE... RESULTING IN AN PRECIPITATED OPIOID WITHDRAWAL. WITHDRAWAL
63 THEREFORE, SUBOXONE CAN NOT BE ABUSED... OR DIVERTED WITHOUT CREATING AN IMMEDIATE PHYSICAL WITHDRAWAL. WITHDRAWAL
64 THE ADDITION OF NALOXONE ALSO MAKES SUBOXONE SAFE FROM POTENTIAL DRUG OVERDOSING. HOWEVER, THE COMBINED USE OF ALCOHOL OR ANTI -ANXIETY AGENTS ( BENZODIAZEPINES ) WITH SUBOXONE IS DANGEROUS AND WILL INCREASE THE RISK OF DRUG OVERDOSE!!! OVERDOSE
65 OUR GREATEST ENEMY IN FIGHTING SUBSTANCE USE AND RELAPSE... IS NOT THE DRUG... BUT THE PERSON S REFUSAL TO FACE THE TRUTH ABOUT WHAT THE DRUG IS DOING TO THEM... OUR REAL ENEMY IS DENIAL! REMEMBER... KNOWLEDGE IS POWER!
66 CONTACT INFORMATION : CARL M. DAWSON, M.S., MAC, LPC 1320 E. KINGSLEY SUITE A SPRINGFIELD, MO ( )
67 References and Suggested Readings U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment TREATMENT IMPROVEMENT PROTOCOL (TIP) SERIES Rockwall II, 5600 Fishers Lane Rockville, MD 20857
68 American Psychiatric Association. (2000 ). Diagnostic and statistical manual of mental disorders (4 th ed). Washington, DC: American Psychiatric Association. Buelow, G., Herbert Suzanne (1995). Counselor s Resource on Psychiatric Medications, Issues of Treatment and Referral. Brooks/Cole Publishing Co., Pacific Grove, Ca. Buprenophine.samhsa.gov Galanter, M., Kleber, H. ( 2008). Textbook of Substance Abuse Treatment. 4 th ed., American Psychiatric Publishing, Inc., Washington, D.C.
69 National Institute on Drug Abuse ( NIDA). Selected Prescription Drugs with Potential for Abuse, and Preventing and Recognizing Prescription Drug Abuse, and Prescription and Over-the-Counter Medications Stahl, S.M. (2003), Essential Psychopharmacology, Neuroscientific Basis and Practical Applications (2 nd ed). Cambridge University Press. Strain, E.C., Stizer M.L. (eds): The Treatment of Opioid Dependence. Baltimore, MD, Johns hopkins University Press, 2006, pp Erickson, C., ( 2007), The Science of Addiction. W.W. Norton and Company, New York, London. Suboxone.com
70 Kinney, J., ( 2003 ) Loosening the Grip : A Handbook of Alcohol Information. Seventh Ed., McGraw Hill, New York, N.Y.. Ray, O., Ksir, C., ( 2004 ) Drugs, Society, and Human Behavior. Tenth Ed., McGraw Hill, New York, N.Y..
MEDICATIONS USED IN SUBSTANCE USE TREATMENT AND RECOVERY Carl M. Dawson, M.S., MAC, LPC - National Drug Court Institute ( NDCI ) Washington, D. C. - The School of Professional Psychology at Forest Institute
Advanced Treatment for Opioid & Alcohol Dependence John Larson, M.D. Corporate Medical Director Gateway Foundation Background 41 years practicing psychiatry Last 15 in addiction medicine I ve watched a
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
MEDICATION ASSISTED TREATMENT (MAT) STATISTICS: ALCOHOL AND OPIOID USE Last year 33 Iowans died from opioid overdose deaths; an additional 19 individuals died of a heroin overdose. The number of drug overdose
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription
Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair Michael Fishman, MD Director of Young Adult Program How Addiction Takes Hold Large & rapid upsurges in dopamine
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Stefan P. Kruszewski, MD Board Certified in Adult, Geriatric, Adolescent and Addiction Psychiatry, and Addiction Medicine Speaker
Identification, treatment and support for individuals with Alcohol & Drug Addiction in the Community Dr David Jackson Clinic Medical Officer The Hobart Clinic Association Drugs In tonight s context, drugs
12 Steps to Changing Neuropathways Julie Denton Review the neurobiology of the brain Understand the basics of neurological damage to the brain from addiction Understand how medications and psychotherapy
Petrol, paint and other Polydrug inhalants use 237 11 Polydrug use Overview What is polydrug use? Reasons for polydrug use What are the harms of polydrug use? How to assess a person who uses several drugs
Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
PATHWAYS TO RECOVERY PATHWAYS TO RECOVERY When Faces & Voices of Recovery was launched in 2001, our founding goal was to celebrate and honor recovery in all of its diversity. We believe that everyone has
Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition
Page: 1 of 7 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
MAT Counselor Education Course Exam Questions Packet Part 1 Course No: Course Title: Course Objective: MA-1901P1 Medication-Assisted Treatment (MAT) Counselor Education Course Part 1 Includes primer on
Neurotransmitters Made Easy: The Mood Brad Lander PhD, LICDC Clinical Director / Psychologist Talbot Hall - Addiction Medicine at The Ohio State University Wexner Medical Center Key Point #1 Thinking and
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
Heroin Overdose Trends and Treatment Options Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Type date here www.gatewayrehab.org Drug Overdose Deaths Increasing in Allegheny County Roberta Lojak holds
Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison
Karen Drexler, M.D. for the DUMC Alcohol Awareness Task Force ALCOHOLISM AND DEPRESSION Overview What is major depression? What is alcohol dependence? Does depression lead to alcohol dependence? Does alcohol
Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1
UCLA-SAPC Lecture Series March 13, 2015 Gary Tsai, M.D. Medical Director Substance Abuse Prevention and Control Neurobiology 101 Neuroscience of Addiction & Recovery Medication-Assisted Treatment (MAT)
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives Neurobehavioral Aspects of Alcohol Consumption Source: Eighth Special Report to the U.S. Congress on Alcohol and Health Secretary
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. email@example.com What is Vivitrol? An injectable from of naltrexone, which
WORK DYNAMIC The final result of this session is the formulation of the questions that, within the activity of the Let s talk about drugs programme of the la Caixa Welfare Project, you will ask Dr. Rafael
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
Cocaine Introduction Cocaine is a powerful drug that stimulates the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
ISSUE DATE SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Treatment of Alcoholism Why is it important Prevents further to body by getting people off alcohol. Can prevent death. Helps keep health insurance down. Provides assistance so alcoholics don t t have to
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
Conceptualizing and Integrating Medication Assistant Treatment into your Court s Armamentarium Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of Medicine firstname.lastname@example.org
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice
Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT An Outpatient Model OBJECTIVE TO PRESENT A PROTOCOL FOR THE EVALUATION AND TREATMENT OF PATIENTS WHO ARE CHEMICALLY DEPENDENT ON OR SEVERLY
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
EAP Drug Free Workplace Newsletter March 2014 Prescription Drugs: Abuse and Addiction What are some of the commonly abused prescription drugs? Although many prescription drugs can be abused or misused,
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
SC 215 FIGHTING DRUG ADDICTION WITH DRUGS John Bush April 15, 2013 ADDICTION A persistent, compulsive dependence on a behavior or substance Behavioral Compulsive shopping --Compulsive eating Compulsive
The Addicted Brain And what you can do How does addiction happen? Addiction can happen as soon as someone uses a substance The brain releases a neurotransmitter called Dopamine into the system that makes
Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
Medication Assisted Treatment Ned Presnall, MSW, LCSW May 17, 2014 FRONTAL LOBE Consciousness Reasoning Planning Goals Values Sense of Self I NEED TO USE!!!!!!!!!!! FRONTAL LOBE Consciousness Reasoning
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics
Medication Assisted Therapy and Pregnancy: An Introduction Deborah A. Orr, Ph.D. The Center For Drug Free Living Adapted from the NIDA Blending Initiative Curriculum Presentation Objectives Define opioids
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
Healing the Addicted Brain Innovative Addiction Support and Treatment Harold C. Urschel III MD, MMA Chief Medical Strategist - Enterhealth 1 Credentials Author of The New York Times best seller, Healing
Substance-Related Disorders DSM-V Many people use words like alcoholism, drug dependence and addiction as general descriptive terms without a clear understanding of their meaning. What does it really mean
Tribal Law and Policy Institute: 5th Annual Tribal Healing to Wellness Court Enhancement Training Neuropharmacology of Addiction Kim McGinnis, PhD Chief Judge, Pueblo of Pojoaque Tribal Court I. Background
visited on Page 1 of 5 LEARN MORE (HTTP://WWW.NAMI.ORG/LEARN-MORE) FIND SUPPORT (HTTP://WWW.NAMI.ORG/FIND-SUPPORT) GET INVOLVED (HTTP://WWW.NAMI.ORG/GET-INVOLVED) DONATE (HTTPS://NAMI360.NAMI.ORG/EWEB/DYNAMICPAGE.ASPX?
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
Module 2: Understanding Addiction, Recovery, and Recovery Oriented Systems of Care This module reviews the processes involved in addiction and what is involved in recovering an addiction free lifestyle.
Integrated System of Care Universal Dual Diagnosis Capabilities Principles of Empathy and Hope Motivational Interviewing Approach Stages of Change Model Design Solution Focused Strength Based Skill Building
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
SUBOXONE /VIVITROL WEBINAR Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12 WEBINAR INTRODUCTIONS Cynthia Parsons- Program Manager
Your consent to our cookies if you continue to use this website.